"Hengrui Medicine: Subsidiary RSS0393 Ointment Clinical Trial Approved"

On September 4th, Hutchison China MediTech announced that its subsidiary, Rui Shi Biotechnology Co., Ltd., had received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for the RSS0393 ointment, and will soon begin clinical trials. The RSS0393 ointment is a proprietary ointment developed by the company containing a small molecule inhibitor of PDE4. After application, it can relieve tissue damage and inflammation by inhibiting the activity of PDE4 in various cells.